MT-201

DRUG2 trials

Sponsors

Mirador Therapeutics, Inc.

Conditions

Crohn's DiseaseHealthy VolunteerInflammatory Bowel Disease (IBD)Ulcerative Colitis (UC)

Phase 1

A First-in-Human Single and Multiple Ascending Dose Study of MT-201

RecruitingNCT07219368

Mirador Therapeutics, Inc.Healthy Volunteer

Start: 2025-10-08End: 2026-12-31Target: 72Updated: 2025-11-04

Phase 2

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

RecruitingNCT07113522

Mirador Therapeutics, Inc.Crohn's Disease, Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)

Start: 2025-06-26End: 2028-02-04Target: 140Updated: 2026-03-12